Dominique started his career as a General Practitioner in France. He joined GSK in 19961 from Ciba Geigy, where he held various marketing and management positions. In 2000, Dominique was appointed General Manager of GSK France. He then became SVP, Southern & Eastern Europe Area Director and then Head of GSK Personalised Medicine Strategy.
Deborah joined GSK in 19962 and is3 currently4 SVP Primary Care in US Pharmaceuticals,5 prior to which she led the US6 Vaccines business. She7 brings a wealth of experience to ViiV8 Healthcare9 having lived and worked in Europe10, Asia11 and the USA12 and a strong13 track record of performance in both14 specialty and primary care. She led the HIV15 business in the UK16 before heading the HIV Centre of Excellence for Pharma17 Europe, and held international roles as General Manager of Australia18 and New Zealand19 and SVP Central and Eastern Europe.
Andrew Witty, Chief Executive Officer, GSK, said: “I want to thank Dominique for the success achieved under his leadership. Since he became CEO of ViiV Healthcare at its creation seven years ago20, the business has successfully launched new medicines, established an innovative pipeline and built a strong reputation with healthcare professionals and the HIV community. With these foundations in place, Dominique leaves ViiV Healthcare in a great position. Emma21 and I are delighted that Deborah22 will be his successor. She is a dynamic leader who has a real passion to deliver for patients and customers and we are confident that she will continue to develop the business successfully to make a difference for people living with HIV, their families and society as a whole.”
Dominique Limet said: “Establishing23 and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy. We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business. The future looks extremely promising for ViiV Healthcare.”
David Redfern24, Chairman of ViiV Healthcare, said: “Dominique has been an outstanding leader of ViiV Healthcare. He has helped to create an entirely new company at the forefront of HIV research and treatment development, with a culture that both inspires and delivers strong business performance. I have very much enjoyed working with him and wish him the very best for the future25.
I also look forward to working with Deborah, a leader who is known for listening to the customer and to her teams, and someone I know is very passionate about innovation in HIV therapy and access.”
Deborah Waterhouse said: “ViiV Healthcare26 has an impeccable reputation for strong performance and a culture that thrives on challenge. I’m honoured to have the opportunity to lead such an exciting endeavour, and to build on the advances that Dominique and the ViiV Healthcare organisation have made to HIV treatment and care.”
Cheryl MacDiarmid2728 29has been appointed to succeed Deborah as SVP US Pharmaceuticals Primary Care. Cheryl has served as VP US Primary Care Sales since early 2015 and been instrumental in shaping the US Primary Care strategy, delivering performance and renewing the culture of patient and customer focus. She brings 20 years of deep experience in establishing key brands and building businesses in the US and Canada, and is known for creating and leading engaged, high-performing teams.
GSK30 – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
ViiV Healthcare - a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.
References
- Savic M, Penders Y, Shi T, Branche A, Pirçon J-Y. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis, Influenza Other Respir Viruses 2022 2023; 17:e13031
- Falsey, AR et al. Respiratory syncytial virus infection in elderly and high-risk adults, in New Engl J Med 2005; 352:1749-59
- Richard Osei-Yeboah et al, Respiratory syncytial virus-associated hospitalisation in adults with comorbidities in two European countries, PROMISE investigators, preprint, August 2023
- ref 4
- ref 5 here
- ref 6
- ref 7
- ref 8
- ref 9
- ref 10
- ref 11
- ref 12
- ref13
- ref 14 here
- ref 15 displayed here.
- ref16
- ref 17 17 17
- ref 18
- ref 19 displayed here.
- ref 20
- ref 21 dsplayed here
- ref 22
- ref 23 mSavic M, Penders Y, Shi T, Branche A, Pirçon J-Y. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis, Influenza Other Respir Viruses 2022 2023; 17:e13031
- ref 24
- ref 25 is displayed here.
ref 26
ref 27
- ref 28
- reference 29.
- ref 30 - this is the last one.
full width image and video promo
full width image promo v2
desc
